A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701

GlaxoSmithKline35 enrolled

Overview

This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B\*5701 can reduce the incidence of hypersensitivity reactions to abacavir). This study aims to collect data on approximately 35 subjects who withdrew from CNA106030 when found to be HLA-B\*5701 positive. HIV disease management and adverse event data in these subjects, where the risk/benefit ratio of treatment with abacavir may alter subsequent prescribing, will be collected

Study Type

OBSERVATIONAL

Enrollment

Conditions

HIV Infection

Interventions

No Intervention -- Observational studyDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who have received notification not to receive abacavir in the CNA106030 study because of a positive HLA-B\*5701 screen result, and were subsequently withdrawn from protocol CNA106030. * Subjects willing and able to understand and provide written informed consent prior to participation in this study. * French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. Exclusion criteria: * Subjects who were not enrolled in the CNA106030 study * Subjects who are not HLA-B\*5701 positive * Subjects who do not consent to being told their HLA-B\*5701 status

Locations (25)

GSK Investigational Site

Graz, Austria

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.